31 March 2021 - Prophylaxis study
Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study
et al., Diabetes Research and Clinical Practice, doi:10.1016/j.diabres.2020.108619 (Peer Reviewed)
Retrospective 328 COVID-19 patients with type 2 diabetes in China, showing significantly lower risk of ARDS with existing metformin use.
|
risk of death, 46.0% lower, RR 0.54, p = 0.40, treatment 3 of 74 (4.1%), control 10 of 74 (13.5%), NNT 11, adjusted per study, mixed effect Cox, propensity score matching.
|
|
risk of ARDS, 80.2% lower, RR 0.20, p = 0.02, treatment 8 of 74 (10.8%), control 17 of 74 (23.0%), NNT 8.2, adjusted per study, odds ratio converted to relative risk, mixed effect Cox, propensity score matching.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Jiang et al., 3/31/2021, retrospective, China, Asia, peer-reviewed, 12 authors.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.